Protaq Biomedical Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 17 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.00 M
- Revenue Growth -59.67%
- Profit Growth -42.21%
- Ebitda -54.01%
- Net Worth 3.10%
- Total Assets -15.99%
About Protaq Biomedical
Protaq Biomedical Private Limited (PBPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 August 2007 and has a history of 17 years and six months. Its registered office is in Gurugram, Haryana, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.00 M.
Ashok Kumar and Mahabir Singh serve as directors at the Company.
Company Details
- Location
Gurugram, Haryana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24233HR2007PTC037110
- Company No.
037110
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Aug 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Protaq Biomedical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashok Kumar  | Director | 14-Aug-2007 | Current |
| Mahabir Singh | Director | 14-Aug-2007 | Current |
Financial Performance of Protaq Biomedical.
Protaq Biomedical Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 59.67% decrease. The company also saw a substantial fall in profitability, with a 42.21% decrease in profit. The company's net worth moved up by a moderate rise of 3.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Protaq Biomedical?
In 2023, Protaq Biomedical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.00 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of Patiala : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 10 Jan 2014 | State Bank Of Patiala | ₹1.00 M | Open |
How Many Employees Work at Protaq Biomedical?
Unlock and access historical data on people associated with Protaq Biomedical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Protaq Biomedical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Protaq Biomedical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.